A dust-up with the New York state attorney general earlier this year got all the attention, but GNC Holdings CEO Mike Archbold says it was “largely self-inflicted wounds” behind the Pittsburgh-based health and wellness retailer’s disappointing first quarter.
In a media phone briefing Thursday, Mr. Archbold pointed to the Downtown-based company’s reduced engagement with customers — down by one-third compared with a year earlier — as a key factor behind a drop in sales revenue.
GNC reported $670.2 million in consolidated revenue for the three months, down from $674.5 million in 2014, with its manufacturing/wholesale segment seeing a 10.4 percent decrease in revenue. In addition, same-store sales — defined as sales only at stores that have been open at least a year — dropped 4.1 percent in domestic company-owned stores, while franchise stores saw a 1.5 percent decrease.
“To be clear, this was our mistake,” Mr. Archbold said.
And GNC didn’t come close to meeting Wall Street’s expectations. Net income dropped to $63.3 million, or 72 cents per share, for the quarter, as compared to $69.9 million, or 75 cents per share, during the same period last year.
Analysts had been looking, on average, for 81 cents per share, according to Thomson Financial.
Operating income for the quarter was $109.6 million, down from just under $121.3 million in 2014.
Mr. Archbold took over GNC’s reins in August and set out to pull back on what he believed was a marketing strategy too dependent on promotions, something he said also played a role in the disappointing first quarter results.
Efforts to assess and test a new marketing strategy, he said, “caused us to talk to our customers less. A lot less.”
He expects to see progress in the latter half of the year. One area Mr. Archbold plans to address is the disparity between sales in the high-performing and low-performing stores. “That level of inconsistency is not acceptable to us.”
The company has now widened its earnings-per-share outlook for fiscal 2015 from a range of $3.10 to $3.15 to a range of $3 to $3.15.
GNC and three other retailers came under fire in New York earlier this year for selling some Herbal Plus supplements that reportedly did not contain the herbs listed on their labels. GNC took issue with the charge, saying the products were botanical extracts that made it unlikely the herb DNA would be detected.
In March, GNC agreed to implement additional testing of its supplements that will exceed FDA requirements as part of an agreement it reached with New York officials.
Shares of GNC closed at $43.05, down $3.86, or 8.23 percent.
Steve Twedt: stwedt@post-gazette.com or 412-263-1963.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.